Your browser doesn't support javascript.
loading
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Mai, Elias K; Miah, Kaya; Bertsch, Uta; Dürig, Jan; Scheid, Christof; Weisel, Katja C; Kunz, Christina; Munder, Markus; Lindemann, Hans-Walter; Merz, Maximilian; Hose, Dirk; Jauch, Anna; Seckinger, Anja; Luntz, Steffen; Sauer, Sandra; Fuhrmann, Stephan; Brossart, Peter; Elmaagacli, Ahmet; Goerner, Martin; Bernhard, Helga; Hoffmann, Martin; Raab, Marc S; Blau, Igor W; Hänel, Mathias; Benner, Axel; Salwender, Hans J; Goldschmidt, Hartmut.
Afiliação
  • Mai EK; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Miah K; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
  • Bertsch U; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Dürig J; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Scheid C; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.
  • Weisel KC; Department of Hematology, University Clinic Essen, Essen, Germany.
  • Kunz C; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
  • Munder M; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lindemann HW; Department of Hematology, Oncology and Immunology, University Hospital Tübingen, Tübingen, Germany.
  • Merz M; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hose D; Institute of Child Nutrition, Max Rubner Institute, Federal Research Institute of Nutrition and Food, Karlsruhe, Germany.
  • Jauch A; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany.
  • Seckinger A; Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany.
  • Luntz S; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Sauer S; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Fuhrmann S; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
  • Brossart P; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Elmaagacli A; Coordination Centre for Clinical Trials, University Hospital Heidelberg, Heidelberg, Germany.
  • Goerner M; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Bernhard H; Department of Hematology and Oncology, Helios Hospital Berlin Buch, Berlin, Germany.
  • Hoffmann M; University Hospital Bonn, Bonn, Germany.
  • Raab MS; Department of Hematology and Oncology, Asklepios Hospital Hamburg St. Georg, Hamburg, Germany.
  • Blau IW; Department of Hematology, Oncology and Palliative Care, Klinikum Bielefeld, Bielefeld, Germany.
  • Hänel M; Department of Internal Medicine V, Klinikum Darmstadt, Darmstadt, Germany.
  • Benner A; Medical Clinic A, Klinikum Ludwigshafen, Ludwigshafen, Germany.
  • Salwender HJ; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Goldschmidt H; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.
Leukemia ; 35(12): 3636, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34785794
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article